Jamshedpur Reporter

Advanced Kidney Cancer Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs and Companies

 Breaking News
  • No posts were found

Advanced Kidney Cancer Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs and Companies

June 17
19:00 2024
Advanced Kidney Cancer Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs and Companies

DelveInsight’s, “Advanced Kidney Cancer Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Advanced Kidney Cancer pipeline landscape. It covers the Advanced Kidney Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Kidney Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Advanced Kidney Cancer research. Learn more about our innovative pipeline today! @ Advanced Kidney Cancer Pipeline Outlook

 

Key Takeaways from the Advanced Kidney Cancer Pipeline Report

  • June 2024:- Michael B. Atkins, MD– This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and nivolumab in treatment naïve patients with metastatic ccRCC. The study will plan to enroll 120 eligible patients randomized in a 2:1 fashion to Arm A and Arm B.
  • June 2024:- Eisai Inc.– The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review [IIR] using Response Evaluation Criteria in Solid Tumors [RECIST 1.1]) as first-line treatment in participants with advanced renal cell carcinoma (RCC).
  • June 2024:- Hoffmann-La Roche– This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (also known as RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib, as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).
  • June 2024:- Ipsen– The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.
  • June 2024:- Incyte Corporation– A Phase 2 Study Evaluating INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive. This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors.
  • DelveInsight’s Advanced Kidney Cancer pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Advanced Kidney Cancer treatment.
  • The leading Advanced Kidney Cancer Companies such as Janux Therapeutics, Infinity Pharmaceuticals, Merck Sharp & Dohme, Xencor, Exelixis, X4 Pharmaceuticals, Nykode Therapeutics Tarus Therapeutics, AstraZeneca, RemeGen, NiKang Therapeutics, NGM Biopharmaceuticals, MedImmune, and others.
  • Promising Advanced Kidney Cancer Therapies such as HB0025, Ipilimumab, Nivolumab, Belzutifan, Botensilimab, Balstilimab, Ipilimumab, ST-1898 tablets, Everolimus, and others.

 

Stay informed about the cutting-edge advancements in Advanced Kidney Cancer treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Kidney Cancer Clinical Trials Assessment

 

Advanced Kidney Cancer Emerging Drugs Profile

 

  • Savolitinib: AstraZeneca

Savolitinib is an oral, potent, and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations or gene amplification. The drug is currently being evaluated under Phase III clinical trial for the treatment of advanced kidney cancer.

 

  • Relatlimab: Bristol-Myers Squibb

Relatlimab is a lymphocyte activation gene-3 (LAG-3) blocking antibody and is expressed in a recombinant CHO cell line. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with advanced kidney cancer.

 

  • JANX008: Janux Therapeutics

JANX008 is an EGFR-TRACTr that is designed to overcome CRS and known on-target EGFR healthy tissue toxicities. Epidermal growth factor receptor (EGFR) is a clinically validated target highly expressed on many solid tumors that are being underserved by current therapies. JANX008 targets EGFR for the treatment of multiple solid cancers including, but not limited to, colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). The drug is currently being evaluated under Phase I clinical trial for the treatment of Advanced Kidney Cancer.

 

Learn more about Advanced Kidney Cancer Drugs opportunities in our groundbreaking Advanced Kidney Cancer research and development projects @ Advanced Kidney Cancer Unmet Needs

 

Advanced Kidney Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

 

Advanced Kidney Cancer Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

 

Discover the latest advancements in Advanced Kidney Cancer treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Advanced Kidney Cancer Market Drivers and Barriers, and Future Perspectives

 

Scope of the Advanced Kidney Cancer Pipeline Report

  • Coverage- Global
  • Advanced Kidney Cancer Companies- Janux Therapeutics, Infinity Pharmaceuticals, Merck Sharp & Dohme, Xencor, Exelixis, X4 Pharmaceuticals, Nykode Therapeutics Tarus Therapeutics, AstraZeneca, RemeGen, NiKang Therapeutics, NGM Biopharmaceuticals, MedImmune, and others.
  • Advanced Kidney Cancer Therapies- HB0025, Ipilimumab, Nivolumab, Belzutifan, Botensilimab, Balstilimab, Ipilimumab, ST-1898 tablets, Everolimus, and others.
  • Advanced Kidney Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Advanced Kidney Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Kidney Cancer pipeline on our website @ Advanced Kidney Cancer Emerging Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Kidney Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Kidney Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Savolitinib: AstraZeneca
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Relatlimab: Bristol-Myers Squibb
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. JANX008: Janux Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Advanced Kidney Cancer Key Companies
  21. Advanced Kidney Cancer Key Products
  22. Advanced Kidney Cancer- Unmet Needs
  23. Advanced Kidney Cancer- Market Drivers and Barriers
  24. Advanced Kidney Cancer- Future Perspectives and Conclusion
  25. Advanced Kidney Cancer Analyst Views
  26. Advanced Kidney Cancer Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/